ANXO signed a joint development agreement for nephrology medicine with Chinese NS company. Mutual cooperation will be carried out in the region of Mainland China. ANXO is in charge of technology develpoment and NS company is responsible for registration and marketing. Based on this agreement, the relation of two companies has been strengthened. Now, both are planning to find further cooperating opportunities on other products as well.

NS company is focus on developmemt and sales of New drug and Generic drug. Key products include Antitumor drugs, Cardiovascular medication, Anti-infective drugs, Rheumatoid immunity medication etc. Many new drug products have been launched in Mainland China. This August, NS company has been elected as one of "the best 100 pharnaceutical companies in China in 2017".